TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides

Exclusion Criteria

• •Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breastfeeding. Females of childbearing potential must agree to take a urine pregnancy test (must be negative) at the Screening visit. Females of childbearing potential include anyone who has experienced menarche and who has not undergone successful surgical sterilization or is not post-menopausal for more than 2 years.
• •Having any active electrical implant anywhere in the body
• •Having a permanent implant in the treated area or an injected chemical substance.
• •Having a history of diseases stimulated by heat unless treatment is conducted following a prophylactic regimen.
• •Use of non-steroidal anti-inflammatory drugs one week before and after each treatment session.
• •Use of retinoids, antioxidants or skin nourishing supplements within 1 month of treatment or during the study.
• •Having received a facial dermabrasion or chemical peel treatment within 2 months of treatment or during the study.
• •Having received treatment with light, RF or other devices in the treated area within 6 months of treatment or during the study.
• •Having received Botox in the treated area within 6 months or collagen/Hyaluronic Acid within a year of treatment or during the study.
• •Having undergone a resurfacing procedure, face lift or eyelid surgery within a year of treatment or during the study.
• •Having undergone any other surgery in the treated area within 6 months of treatment (or more if skin has not healed completely) or during the study.
• •Having ever received fat injections or other methods of augmentation with injected or implanted material in the treated area or planning to during the study.
• •History of keloid scarring or of abnormal wound healing.
• •Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
• •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
• •History of epidermal or dermal disorders.
• •History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
• •Suffering from hormonal imbalance, as per the Investigator's discretion.
• •Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course.
• •Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
• •Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders.
• •Vascular lesion, tattoo or permanent make-up in the treated area.
• •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
• •Participation in a study of another device or drug within 1 month prior to enrollment or during the study.
• •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.